You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
McKinsey
Johnson and Johnson
McKesson
Merck

Last Updated: February 23, 2024

CLINICAL TRIALS PROFILE FOR CONTRAVE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Contrave

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00563563 ↗ A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent Completed Orexigen Therapeutics, Inc Phase 2 2007-10-01 The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in the treatment of nicotine-dependence in overweight and obese subjects.
NCT01601704 ↗ Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study) Terminated Orexigen Therapeutics, Inc Phase 3 2012-06-01 The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and obese subjects who are at a higher risk of having these events because they have diabetes and/or other cardiovascular risk factors.
NCT02259179 ↗ Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers Completed Orexigen Therapeutics, Inc Phase 1 2014-09-01 This is a Phase 1, open-label, randomized, single-dose, 2-way crossover study in healthy adult subjects to assess the bioequivalence of naltrexone SR/bupropion SR combination trilayer tablets prepared at two different manufacturing sites. The pharmacokinetics of the two drug products will be evaluated separately in the fed and fasted state.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Contrave

Condition Name

Condition Name for Contrave
Intervention Trials
Obesity 13
Binge-eating Disorder 4
Loss-of-control Eating 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Contrave
Intervention Trials
Obesity 9
Overweight 7
Feeding and Eating Disorders 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Contrave

Trials by Country

Trials by Country for Contrave
Location Trials
United States 92
Canada 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Contrave
Location Trials
Connecticut 7
California 4
Ohio 4
Kansas 3
Maryland 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Contrave

Clinical Trial Phase

Clinical Trial Phase for Contrave
Clinical Trial Phase Trials
Phase 4 7
Phase 3 2
Phase 2/Phase 3 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Contrave
Clinical Trial Phase Trials
Not yet recruiting 6
Active, not recruiting 4
Recruiting 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Contrave

Sponsor Name

Sponsor Name for Contrave
Sponsor Trials
Yale University 6
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 6
Orexigen Therapeutics, Inc 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Contrave
Sponsor Trials
Other 21
NIH 6
Industry 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Mallinckrodt
Colorcon
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.